$MGNX
MacroGenics Inc Stock $mgnx

$mgnx Overview Financials Valuation SEC Filings Company Website

2024 Q4 Form 10-Q Financial Statement

#000112534524000160 Filed on November 05, 2024

Income Statement

Concept	2024 Q4	2024 Q3
Revenue		$110.7M
YoY Change		964.81%
Cost Of Revenue		$168.0K
YoY Change		97.65%
Gross Profit		$110.5M
YoY Change		971.96%
Gross Profit Margin		99.85%
Selling, General & Admin		$14.10M
YoY Change		13.74%
% of Gross Profit		12.76%
Research & Development		$40.54M
YoY Change		34.56%
% of Gross Profit		36.68%
Depreciation & Amortization		$1.835M
YoY Change		-5.9%
% of Gross Profit		1.66%
Operating Expenses		$40.54M
YoY Change		34.56%
Operating Profit		$54.19M
YoY Change		-252.64%
Interest Expense		$0.00
YoY Change
% of Operating Profit		0.0%
Other Income/Expense, Net		$2.118M
YoY Change		-31.68%
Pretax Income		$56.31M
YoY Change		219.94%
Income Tax
% Of Pretax Income
Net Earnings		$56.31M
YoY Change		220.78%
Net Earnings / Revenue		50.86%
Basic Earnings Per Share		$0.90
Diluted Earnings Per Share		$0.90
COMMON SHARES
Basic Shares Outstanding	62.76M shares	62.72M shares
Diluted Shares Outstanding		62.87M shares

Balance Sheet

Concept	2024 Q4	2024 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments		$200.4M
YoY Change		-21.86%
Cash & Equivalents		$179.6M
Short-Term Investments		$20.74M
Other Short-Term Assets		$9.839M
YoY Change		15.75%
Inventory		$3.244M
Prepaid Expenses
Receivables		$8.750M
Other Receivables		$0.00
Total Short-Term Assets		$222.2M
YoY Change		-23.73%
LONG-TERM ASSETS
Property, Plant & Equipment		$19.10M
YoY Change		-15.61%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets		$1.185M
YoY Change		-14.56%
Total Long-Term Assets		$42.30M
YoY Change		-13.07%
TOTAL ASSETS
Total Short-Term Assets		$222.2M
Total Long-Term Assets		$42.30M
Total Assets		$264.5M
YoY Change		-22.2%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable		$6.613M
YoY Change		100.21%
Accrued Expenses		$24.64M
YoY Change		-3.27%
Deferred Revenue		$23.31M
YoY Change		25.42%
Short-Term Debt		$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities		$59.31M
YoY Change		15.63%
LONG-TERM LIABILITIES
Long-Term Debt		$0.00
YoY Change
Other Long-Term Liabilities		$258.0K
YoY Change		0.0%
Total Long-Term Liabilities		$258.0K
YoY Change		0.0%
TOTAL LIABILITIES
Total Short-Term Liabilities		$59.31M
Total Long-Term Liabilities		$258.0K
Total Liabilities		$144.4M
YoY Change		-1.07%
SHAREHOLDERS EQUITY
Retained Earnings		-$1.154B
YoY Change		9.24%
Common Stock		$1.274B
YoY Change		1.89%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity		$120.1M
YoY Change
Total Liabilities & Shareholders Equity		$264.5M
YoY Change		-22.2%

Cashflow Statement

Concept	2024 Q4	2024 Q3
OPERATING ACTIVITIES
Net Income		$56.31M
YoY Change		220.78%
Depreciation, Depletion And Amortization		$1.835M
YoY Change		-5.9%
Cash From Operating Activities		$60.16M
YoY Change		-270.67%
INVESTING ACTIVITIES
Capital Expenditures		$592.0K
YoY Change		20.82%
Acquisitions
YoY Change
Other Investing Activities		$36.19M
YoY Change		-209.6%
Cash From Investing Activities		$35.60M
YoY Change		-206.17%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities		-68.00K
YoY Change		-100.14%
NET CHANGE
Cash From Operating Activities		60.16M
Cash From Investing Activities		35.60M
Cash From Financing Activities		-68.00K
Net Change In Cash		95.69M
YoY Change		-607.12%
FREE CASH FLOW
Cash From Operating Activities		$60.16M
Capital Expenditures		$592.0K
Free Cash Flow		$59.57M
YoY Change		-266.68%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
	mgnx	Cost Of Manufacturing Services CostOfManufacturingServices	7603000	usd
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	138304000	usd
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	119232000	usd
CY2023Q3	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	12409000	usd
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	43237000	usd
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	39628000	usd
CY2024Q3	us-gaap	Costs And Expenses CostsAndExpenses	56517000	usd
CY2023Q3	us-gaap	Costs And Expenses CostsAndExpenses	45899000	usd
	us-gaap	Costs And Expenses CostsAndExpenses	188350000	usd
CY2024Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	54191000	usd
CY2023Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-35502000	usd
	dei	Amendment Flag AmendmentFlag	false
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2024
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q3
	dei	Entity Central Index Key EntityCentralIndexKey	0001125345
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
	dei	Document Quarterly Report DocumentQuarterlyReport	true
	dei	Document Period End Date DocumentPeriodEndDate	2024-09-30
	dei	Document Transition Report DocumentTransitionReport	false
	dei	Entity Registrant Name EntityRegistrantName	MACROGENICS, INC.
	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	06-1591613
	dei	Entity Address Address Line1 EntityAddressAddressLine1	9704 Medical Center Drive
	dei	City Area Code CityAreaCode	301
	dei	Local Phone Number LocalPhoneNumber	251-5172
	dei	Security12b Title Security12bTitle	Common Stock, par value $0.01 per share
	dei	Trading Symbol TradingSymbol	MGNX
	dei	Security Exchange Name SecurityExchangeName	NASDAQ
	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
	dei	Entity Filer Category EntityFilerCategory	Accelerated Filer
	dei	Entity Small Business EntitySmallBusiness	false
	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
	dei	Entity Shell Company EntityShellCompany	false
CY2024Q4	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	62763448	shares
CY2024Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	179625000	usd
CY2023Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	100956000	usd
CY2023Q4	us-gaap	Investments Investments	128849000	usd
CY2024Q3	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	8750000	usd
CY2023Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	10367000	usd
CY2024Q3	us-gaap	Inventory Net InventoryNet	3244000	usd
CY2023Q4	us-gaap	Inventory Net InventoryNet	1221000	usd
CY2024Q3	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	9839000	usd
CY2023Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	9946000	usd
CY2024Q3	us-gaap	Assets Current AssetsCurrent	222196000	usd
CY2023Q4	us-gaap	Assets Current AssetsCurrent	251339000	usd
CY2024Q3	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	19100000	usd
CY2024Q3	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	4744000	usd
CY2023Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	3775000	usd
CY2024Q3	us-gaap	Liabilities Current LiabilitiesCurrent	59309000	usd
CY2023Q4	us-gaap	Liabilities Current LiabilitiesCurrent	56108000	usd
CY2024Q3	us-gaap	Contract With Customer Liability Noncurrent ContractWithCustomerLiabilityNoncurrent	55503000	usd
CY2023Q4	us-gaap	Contract With Customer Liability Noncurrent ContractWithCustomerLiabilityNoncurrent	59243000	usd
CY2024Q3	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	29356000	usd
CY2023Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	30196000	usd
CY2024Q3	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	258000	usd
CY2023Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	258000	usd
CY2024Q3	us-gaap	Liabilities Liabilities	144426000	usd
CY2023Q4	us-gaap	Liabilities Liabilities	145805000	usd
CY2024Q3	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2023Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2024Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	125000000	shares
CY2023Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	125000000	shares
CY2024Q3	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	62763120	shares
CY2023Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	62070627	shares
CY2024Q3	us-gaap	Common Stock Value CommonStockValue	627000	usd
	dei	Entity Address State Or Province EntityAddressStateOrProvince	MD
CY2024Q3	us-gaap	Investments Investments	20738000	usd
CY2023Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	21847000	usd
CY2024Q3	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	22011000	usd
CY2023Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	23846000	usd
CY2024Q3	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	1185000	usd
CY2023Q4	us-gaap	Assets Assets	298418000	usd
CY2024Q3	us-gaap	Accounts Payable Current AccountsPayableCurrent	6613000	usd
CY2023Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	6443000	usd
CY2024Q3	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	24644000	usd
CY2024Q3	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	23308000	usd
CY2023Q4	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	21651000	usd
CY2023Q4	us-gaap	Common Stock Value CommonStockValue	621000	usd
CY2024Q3	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	1273722000	usd
CY2023Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	1254750000	usd
CY2024Q3	us-gaap	Accumulated Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	14000	usd
CY2023Q4	us-gaap	Accumulated Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	-6000	usd
CY2024Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-1154297000	usd
CY2023Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-1102752000	usd
CY2024Q3	us-gaap	Stockholders Equity StockholdersEquity	120066000	usd
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	152613000	usd
CY2024Q3	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	264492000	usd
CY2023Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	298418000	usd
	us-gaap	Net Income Loss NetIncomeLoss	37014000	usd
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	7745000	usd
	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	3276000	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	14014000	usd
	mgnx	Gain On Royalty Monetization Arrangement GainOnRoyaltyMonetizationArrangement	150930000	usd
	mgnx	Non Cash Interest Expense Recognized NonCashInterestExpenseRecognized	1430000	usd
	mgnx	Operating Lease Noncash Expense OperatingLeaseNoncashExpense	2703000	usd
	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	-423000	usd
	us-gaap	Gain Loss On Disposition Of Assets GainLossOnDispositionOfAssets	-111000	usd
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-30911000	usd
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	-385000	usd
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-1651000	usd
	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	7000	usd
	us-gaap	Increase Decrease In Accounts Payable And Other Operating Liabilities IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities	-1607000	usd
	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	-3388000	usd
	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-723000	usd
	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	13376000	usd
	us-gaap	Payments To Acquire Available For Sale Securities Debt PaymentsToAcquireAvailableForSaleSecuritiesDebt	217216000	usd
	us-gaap	Proceeds From Sale And Maturity Of Available For Sale Securities ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities	99390000	usd
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	1144000	usd
	us-gaap	Proceeds From Sale Of Machinery And Equipment ProceedsFromSaleOfMachineryAndEquipment	64000	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-118906000	usd
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	616000	usd
	mgnx	Proceedsfrom Stock Options Exercised And Espp Purchases ProceedsfromStockOptionsExercisedAndESPPPurchases	279000	usd
	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	306000	usd
	mgnx	Principal Payments On Royalty Monetization Arrangement PrincipalPaymentsOnRoyaltyMonetizationArrangement	156000	usd
	mgnx	Net Proceeds From Sale Of Future Royalties NetProceedsFromSaleOfFutureRoyalties	149655000	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	150088000	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-18986000	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	108884000	usd
CY2024Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	179625000	usd
CY2023Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	89898000	usd
	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	166000	usd
CY2024Q3	us-gaap	Unrealized Gain Loss On Investments UnrealizedGainLossOnInvestments	38000	usd
CY2024Q3	us-gaap	Net Income Loss NetIncomeLoss	56309000	usd
	dei	Entity Address City Or Town EntityAddressCityOrTown	Rockville
CY2023Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	1386000	usd
CY2024Q3	us-gaap	Assets Assets	264492000	usd
CY2023Q3	us-gaap	Net Income Loss NetIncomeLoss	17554000	usd
	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	20850
CY2023Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	24239000	usd
CY2024Q3	us-gaap	Revenues Revenues	110708000	usd
CY2023Q3	us-gaap	Revenues Revenues	10397000	usd
	us-gaap	Revenues Revenues	130609000	usd
	us-gaap	Revenues Revenues	48029000	usd
CY2024Q3	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	168000	usd
CY2023Q3	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	85000	usd
	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	614000	usd
	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	456000	usd
CY2024Q3	mgnx	Cost Of Manufacturing Services CostOfManufacturingServices	1702000	usd
CY2023Q3	mgnx	Cost Of Manufacturing Services CostOfManufacturingServices	3274000	usd
	mgnx	Cost Of Manufacturing Services CostOfManufacturingServices	6195000	usd
CY2024Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	40543000	usd
CY2023Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	30131000	usd
CY2024Q3	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	14104000	usd
	us-gaap	Costs And Expenses CostsAndExpenses	166919000	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-57741000	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-118890000	usd
CY2024Q3	mgnx	Gain On Royalty Monetization Arrangement GainOnRoyaltyMonetizationArrangement	0	usd
CY2023Q3	mgnx	Gain On Royalty Monetization Arrangement GainOnRoyaltyMonetizationArrangement	50000000	usd
	mgnx	Gain On Royalty Monetization Arrangement GainOnRoyaltyMonetizationArrangement	0	usd
	mgnx	Gain On Royalty Monetization Arrangement GainOnRoyaltyMonetizationArrangement	150930000	usd
CY2024Q3	us-gaap	Other Nonoperating Income OtherNonoperatingIncome	2118000	usd
CY2023Q3	us-gaap	Other Nonoperating Income OtherNonoperatingIncome	3056000	usd
	us-gaap	Other Nonoperating Income OtherNonoperatingIncome	7335000	usd
	us-gaap	Other Nonoperating Income OtherNonoperatingIncome	6404000	usd
CY2024Q3	us-gaap	Interest Expense InterestExpense	0	usd
CY2023Q3	us-gaap	Interest Expense InterestExpense	0	usd
	us-gaap	Interest Expense InterestExpense	1139000	usd
	us-gaap	Interest Expense InterestExpense	1430000	usd
CY2024Q3	us-gaap	Net Income Loss NetIncomeLoss	56309000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-51545000	usd
	us-gaap	Net Income Loss NetIncomeLoss	37014000	usd
CY2024Q3	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	38000	usd
CY2023Q3	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	38000	usd
	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	20000	usd
	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	-30000	usd
CY2024Q3	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	56347000	usd
CY2023Q3	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	17592000	usd
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-51525000	usd
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	36984000	usd
CY2024Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.90
CY2023Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.28
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.82
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.60
CY2024Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.90
CY2023Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.28
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.82
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.60
CY2024Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	62744005	shares
CY2023Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	61980680	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	62566723	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	61890824	shares
CY2024Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	62865841	shares
CY2023Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	62244602	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	62566723	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	62090343	shares
CY2023Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	152613000	usd
CY2024Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	5512000	usd
CY2024Q1	mgnx	Stock Issued During Period Value Stock Plan Activity StockIssuedDuringPeriodValueStockPlanActivity	248000	usd
CY2024Q1	us-gaap	Unrealized Gain Loss On Investments UnrealizedGainLossOnInvestments	-29000	usd
CY2024Q1	us-gaap	Net Income Loss NetIncomeLoss	-52190000	usd
CY2024Q1	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	106154000	usd
CY2024Q2	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	6693000	usd
CY2024Q2	mgnx	Stock Issued During Period Value Stock Plan Activity StockIssuedDuringPeriodValueStockPlanActivity	625000	usd
CY2024Q2	us-gaap	Unrealized Gain Loss On Investments UnrealizedGainLossOnInvestments	11000	usd
CY2024Q2	us-gaap	Net Income Loss NetIncomeLoss	-55664000	usd
CY2024Q2	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	57819000	usd
CY2024Q3	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	5969000	usd
CY2024Q3	mgnx	Stock Issued During Period Value Stock Plan Activity StockIssuedDuringPeriodValueStockPlanActivity	-69000	usd
CY2024Q3	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	120066000	usd
CY2022Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	142013000	usd
CY2023Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	4788000	usd
CY2023Q1	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	617000	usd
CY2023Q1	mgnx	Stock Issued During Period Value Stock Plan Activity StockIssuedDuringPeriodValueStockPlanActivity	-154000	usd
CY2023Q1	us-gaap	Unrealized Gain Loss On Investments UnrealizedGainLossOnInvestments	13000	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-38009000	usd
CY2023Q1	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	109268000	usd
CY2023Q2	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	4436000	usd
CY2023Q2	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	235000	usd
CY2023Q2	mgnx	Stock Issued During Period Value Stock Plan Activity StockIssuedDuringPeriodValueStockPlanActivity	216000	usd
CY2023Q2	us-gaap	Unrealized Gain Loss On Investments UnrealizedGainLossOnInvestments	-80000	usd
CY2023Q2	us-gaap	Net Income Loss NetIncomeLoss	57469000	usd
CY2023Q2	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	171544000	usd
CY2023Q3	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	4746000	usd
CY2023Q3	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	187000	usd
CY2023Q3	mgnx	Stock Issued During Period Value Stock Plan Activity StockIssuedDuringPeriodValueStockPlanActivity	-89000	usd
CY2023Q3	us-gaap	Unrealized Gain Loss On Investments UnrealizedGainLossOnInvestments	38000	usd
CY2023Q3	us-gaap	Net Income Loss NetIncomeLoss	17554000	usd
CY2023Q3	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	193980000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-51545000	usd
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	5487000	usd
	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	2625000	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	18174000	usd
	mgnx	Gain On Royalty Monetization Arrangement GainOnRoyaltyMonetizationArrangement	0	usd
	mgnx	Non Cash Interest Expense Recognized NonCashInterestExpenseRecognized	0	usd
	mgnx	Operating Lease Noncash Expense OperatingLeaseNoncashExpense	1835000	usd
	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	-2000	usd
	us-gaap	Gain Loss On Disposition Of Assets GainLossOnDispositionOfAssets	57000	usd
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-1616000	usd
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	2023000	usd
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-108000	usd
	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	-200000	usd
	us-gaap	Increase Decrease In Accounts Payable And Other Operating Liabilities IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities	170000	usd
	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	648000	usd
	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	128000	usd
	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	-2084000	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-29966000	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-50168000	usd
	us-gaap	Payments To Acquire Available For Sale Securities Debt PaymentsToAcquireAvailableForSaleSecuritiesDebt	63394000	usd
	us-gaap	Proceeds From Sale And Maturity Of Available For Sale Securities ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities	174150000	usd
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	3086000	usd
	us-gaap	Proceeds From Sale Of Machinery And Equipment ProceedsFromSaleOfMachineryAndEquipment	160000	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	107830000	usd
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	0	usd
	mgnx	Proceedsfrom Stock Options Exercised And Espp Purchases ProceedsfromStockOptionsExercisedAndESPPPurchases	3276000	usd
	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	2471000	usd
	mgnx	Principal Payments On Royalty Monetization Arrangement PrincipalPaymentsOnRoyaltyMonetizationArrangement	0	usd
	mgnx	Net Proceeds From Sale Of Future Royalties NetProceedsFromSaleOfFutureRoyalties	0	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	805000	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	78669000	usd
CY2023Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	100956000	usd
	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	0	usd
CY2024Q3	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis	20724000	usd
CY2024Q3	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	14000	usd
CY2024Q3	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	0	usd
CY2024Q3	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	20738000	usd
CY2023Q4	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis	128855000	usd
CY2023Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	16000	usd
CY2023Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	22000	usd
CY2023Q4	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	128849000	usd
CY2023Q4	us-gaap	Debt Securities Available For Sale Allowance For Credit Loss DebtSecuritiesAvailableForSaleAllowanceForCreditLoss	0	usd
CY2024Q3	us-gaap	Debt Securities Available For Sale Allowance For Credit Loss DebtSecuritiesAvailableForSaleAllowanceForCreditLoss	0	usd
CY2024Q3	us-gaap	Inventory Work In Process InventoryWorkInProcess	2189000	usd
CY2023Q4	us-gaap	Inventory Work In Process InventoryWorkInProcess	261000	usd
CY2024Q3	us-gaap	Inventory Finished Goods InventoryFinishedGoods	1055000	usd
CY2023Q4	us-gaap	Inventory Finished Goods InventoryFinishedGoods	960000	usd
CY2024Q3	us-gaap	Inventory Net InventoryNet	3244000	usd
CY2023Q4	us-gaap	Inventory Net InventoryNet	1221000	usd
CY2024Q3	us-gaap	Inventory Valuation Reserves InventoryValuationReserves	0	usd
CY2023Q4	us-gaap	Inventory Valuation Reserves InventoryValuationReserves	3100000	usd
CY2024Q3	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	5970000	usd
CY2023Q3	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	4790000	usd
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	18174000	usd
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	14014000	usd
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P6Y21D
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P5Y10M17D
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	12223637	shares
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	15.11
CY2023	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P6Y8M12D
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod	1950032	shares
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	16.18
	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	331916	shares
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	9.41
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	141409	shares
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	11.64
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod	259817	shares
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice	22.09
CY2024Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	13440527	shares
CY2024Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	15.30
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P6Y4M24D
CY2024Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	18000	usd
CY2024Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	8970940	shares
CY2024Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	17.66
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1	P5Y4M24D
CY2024Q3	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1	10000	usd
CY2024Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber	12435275	shares
CY2024Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice	15.70
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1	P6Y3M18D
CY2024Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue	16000	usd
CY2024Q3	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized	26300000	usd
	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1 EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1	P1Y4M24D
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	12.79
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	3.78
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	2616000	usd
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	61000	usd
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	3122000	usd
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	87000	usd
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1	13533000	usd
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1	13611000	usd
CY2024Q3	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	14235295	shares
CY2023Q3	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	12607056	shares
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	12514638	shares
CY2024Q3	us-gaap	Net Income Loss NetIncomeLoss	56309000	usd
CY2023Q3	us-gaap	Net Income Loss NetIncomeLoss	17554000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-51545000	usd
	us-gaap	Net Income Loss NetIncomeLoss	37014000	usd
CY2024Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	62744005	shares
CY2023Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	61980680	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	62566723	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	61890824	shares
CY2024Q3	us-gaap	Incremental Common Shares Attributable To Share Based Payment Arrangements IncrementalCommonSharesAttributableToShareBasedPaymentArrangements	121836	shares
CY2023Q3	us-gaap	Incremental Common Shares Attributable To Share Based Payment Arrangements IncrementalCommonSharesAttributableToShareBasedPaymentArrangements	263922	shares
	us-gaap	Incremental Common Shares Attributable To Share Based Payment Arrangements IncrementalCommonSharesAttributableToShareBasedPaymentArrangements	0	shares
	us-gaap	Incremental Common Shares Attributable To Share Based Payment Arrangements IncrementalCommonSharesAttributableToShareBasedPaymentArrangements	199519	shares
CY2024Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	62865841	shares
CY2023Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	62244602	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	62566723	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	62090343	shares
CY2024Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.90
CY2023Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.28
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.82
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.60
CY2024Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.90
CY2023Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.28
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.82
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.60
CY2024Q3	ecd	Non Rule10b51 Arr Adopted Flag NonRule10b51ArrAdoptedFlag	false
CY2024Q3	ecd	Non Rule10b51 Arr Trmntd Flag NonRule10b51ArrTrmntdFlag	false
CY2024Q3	ecd	Rule10b51 Arr Trmntd Flag Rule10b51ArrTrmntdFlag	false

Files In Submission

Name	View Source	Status
FilingSummary.xml	Edgar Link	unprocessable
0001125345-24-000160-index-headers.html	Edgar Link	pending
0001125345-24-000160-index.html	Edgar Link	pending
0001125345-24-000160.txt	Edgar Link	pending
0001125345-24-000160-xbrl.zip	Edgar Link	pending
exhibit101fourthamendmentt.htm	Edgar Link	pending
exhibit102secondletteragre.htm	Edgar Link	pending
exhibit31-1q32024.htm	Edgar Link	pending
exhibit31-2q32024.htm	Edgar Link	pending
exhibit32-1q32024.htm	Edgar Link	pending
exhibit32-2q32024.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
mgnx-20240930.htm	Edgar Link	pending
mgnx-20240930.xsd	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
mgnx-20240930_cal.xml	Edgar Link	unprocessable
mgnx-20240930_def.xml	Edgar Link	unprocessable
mgnx-20240930_lab.xml	Edgar Link	unprocessable
mgnx-20240930_pre.xml	Edgar Link	unprocessable
mgnx-20240930_htm.xml	Edgar Link	completed
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$MGNX
MacroGenics Inc Stock $mgnx

2024 Q4 Form 10-Q Financial Statement

#000112534524000160 Filed on November 05, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$MGNX MacroGenics Inc Stock $mgnx

2024 Q4 Form 10-Q Financial Statement

#000112534524000160 Filed on November 05, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$MGNX
MacroGenics Inc Stock $mgnx